ClinConnect ClinConnect Logo
Search / Trial NCT06609980

Restoration of Antibiotics Related Infant Microbiota Perturbations by Autologous Fecal Transplant

Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Sep 19, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Fmt Autologous Children

ClinConnect Summary

This clinical trial is exploring a new way to help restore the healthy gut bacteria in young children who have taken antibiotics. Antibiotics are important medicines that fight infections, but they can also disrupt the balance of good bacteria in the gut, which may lead to health issues later in life, such as allergies or obesity. The researchers believe that by collecting a sample of a child’s gut bacteria before they take antibiotics and then giving it back to them afterward through a simple method (mixing it with milk or formula), it might help their gut bacteria recover more quickly and completely.

The trial is looking for healthy infants and toddlers between 1 month and 4 years old. To participate, children should not have taken antibiotics in the past three months and should not have any documented immune system conditions. If eligible, families can expect a straightforward process that aims to help their child's gut health without causing any discomfort. This innovative approach could help improve the long-term health of young children who need antibiotics.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • healthy infants and toddlers 1 month to 4 years of age (regardless of birth mode, sex, or diet (breastmilk, formula, solids, etc.)
  • Exclusion Criteria:
  • Child's antibiotic use within 3 months before inclusion in the study
  • Documented immunological condition from the child's pediatrician

About Rutgers, The State University Of New Jersey

Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.

Locations

New Brunswick, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Maria Gloria Dominguez-Bello, PhD

Principal Investigator

Rutgers Department of Biochemistry & Microbiology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported